Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 537

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations

Open access
Teach, Stephen J., Gill, Michelle A., Togias, Alkis, Sorkness, Christine A., Arbes, Samuel J., Calatroni, Agustin, Wildfire, Jeremy J., Gergen, Peter J., Cohen, Robyn T., Pongracic, Jacqueline A., Kercsmar, Carolyn M., Khurana Hershey, Gurjit K., Gruchalla, Rebecca S., Liu, Andrew H., Zoratti, Edward M., Kattan, Meyer, Grindle, Kristine A., Gern, James E., Busse, William W., Szefler, Stanley J.·2015·Journal of Allergy and Clinical Immunology
DOI 10.1016/j.jaci.2015.09.008
Open this paper in CoChat — free account

Abstract

Background Short-term targeted treatment can potentially prevent fall asthma exacerbations while limiting therapy exposure. Objective We sought to compare (1) omalizumab with placebo and (2) omalizumab with an inhaled corticosteroid (ICS) boost with regard to fall exacerbation rates when initiated 4 to 6 weeks before return to school. Methods A 3-arm, randomized, double-blind, double placebo-controlled, multicenter clinical trial was conducted among inner-city asthmatic children aged 6 to 17 years with 1 or more recent exacerbations (clincaltrials.gov #NCT01430403). Guidelines-based therapy was continued over a 4- to 9-month run-in phase and a 4-month intervention phase. In a subset the effects of omalizumab on IFN-α responses to rhinovirus in PBMCs were examined. Results Before the falls of 2012 and 2013, 727 children were enrolled, 513 were randomized, and 478 were analyzed. The fall exacerbation rate was significantly lower in the omalizumab versus placebo arms (11.3% vs 21.0%; odds ratio [OR], 0.48; % CI, 0.25–.92), but there was no significant difference between omalizumab and ICS boost (8.4% vs 11.1%; OR, 0.73; 95% CI, 0.33–1.64). In a prespecified subgroup analysis, among participants with an exacerbation during the run-in phase, omalizumab was significantly more efficacious than both placebo (6.4% vs 36.3%; OR, 0.12; 95% CI, 0.02–0.64) and ICS boost (2.0% vs 27.8%; OR, 0.05; 95% CI, 0.002–0.98). Omalizumab improved IFN-α responses to rhinovirus, and within the omalizumab group, greater IFN-α increases were associated with fewer exacerbations (OR, 0.14; 95% CI, 0.01–0.88). Adverse events were rare and similar among arms. Conclusions Adding omalizumab before return to school to ongoing guidelines-based care among inner-city youth reduces fall asthma exacerbations, particularly among those with a recent exacerbation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2015.09.008

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 537

Metadata

Authors
Teach, S. J., Gill, M. A., Togias, A., Sorkness, C. A., Arbes, S. J., Calatroni, A., Wildfire, J. J., Gergen, P. J., Cohen, R. T., Pongracic, J. A., Kercsmar, C. M., Khurana Hershey, G. K., Gruchalla, R. S., Liu, A. H., Zoratti, E. M., Kattan, M., Grindle, K. A., Gern, J. E., Busse, W. W., & Szefler, S. J.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2015-12
Volume
136
Issue
6
Pages
1476-1485
ISSN
0091-6749 (ISSN-L)
DOI
10.1016/j.jaci.2015.09.008
OpenAlex
W1876031798
Cited by
537
References
33
FWCI
36.16
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. https://app.cochat.ai/papers/10.1016/j.jaci.2015.09.008
The paper
Teach, S. J., Gill, M. A., Togias, A., Sorkness, C. A., Arbes, S. J., Calatroni, A., Wildfire, J. J., Gergen, P. J., Cohen, R. T., Pongracic, J. A., Kercsmar, C. M., Khurana Hershey, G. K., Gruchalla, R. S., Liu, A. H., Zoratti, E. M., Kattan, M., Grindle, K. A., Gern, J. E., Busse, W. W., & Szefler, S. J. (2015). Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2015.09.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.